Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

315 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2021-04-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NCT00462917

Alzheimer Disease

COMPLETED NA

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667

Mild Cognitive Impairment

COMPLETED NA

SCAN Memory Program Evaluation Study

NCT01182987

Dementia

UNKNOWN NA

Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.

NCT05254873

Alzheimer's Dementia (AD) Family Caregivers

COMPLETED

Learning Amyloid and Tau Results

NCT07222930

Alzheimer Disease

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alzheimer's disease (AD) is a brain disease and is the most common form of dementia. Clinical trials for the prevention of AD have been moving to enroll subjects at increasingly earlier time-points, and are now focusing upon individuals who are not only cognitively normal but also have biomarkers associated with an increased risk of developing AD. Detecting one specific biomarker on brain scans, i.e. amyloid-beta protein, is currently used to inform diagnoses in cognitively impaired individuals, and its use may expand to pre-clinical AD cases as preventive therapies are developed.

In the REVEAL-SCAN clinical trial, the investigators are examining the psychological and behavioral impact of learning "elevated" and "not elevated" amyloid neuroimaging results pertaining to the risk of progressing to Alzheimer's disease dementia by age 85 among cognitively normal older adults. The study's goal is to learn how to communicate these amyloid brain scan results and the risk of developing AD dementia by age 85 in a diverse population of cognitively normal older adults. Findings will be relevant to future decision-making in research trials and clinical practices.

Study sites will enroll older, cognitively normal individuals (approx. 370 total) using APOE genotyping to enrich the enrollment sample such that roughly 100 of those scanned will have elevated amyloid brain scan results. From this enriched sample, participants (approximately 25% African-American) will all receive their Alzheimer's Disease Dementia Risk Assessment based on known risk factors. Half of the participants will be randomized to also learn their amyloid brain scan result at that time, while the other half will learn their scan result 6 months later. Cognitive, psychological, and behavioral outcomes will be compared between these two groups. Participants will be followed for up to 9 months with up to 7 in-person visits and 5 phone calls.

REVEAL-SCAN is the first multisite randomized clinical trial to explore the benefits, risks and limitations of disclosing amyloid results, and will help researchers and clinicians understand downstream implications of this emerging technology as it becomes increasingly utilized to compile comprehensive neuroimaging profiles for older adults at risk for developing Alzheimer's disease dementia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Amyloid Beta-Peptides Risk Assessment Education Neuropsychological Tests Neuroimaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amyloid Brain Imaging Non-Disclosure

Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.

Group Type ACTIVE_COMPARATOR

Alzheimer's Disease Risk Disclosure

Intervention Type BEHAVIORAL

Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Amyloid Brain Imaging Disclosure

Subjects will receive both their "elevated" or "not elevated" amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry.

Group Type EXPERIMENTAL

Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure

Intervention Type BEHAVIORAL

Subjects will learn their own "elevated" or "not elevated" amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alzheimer's Disease Risk Disclosure

Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Intervention Type BEHAVIORAL

Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure

Subjects will learn their own "elevated" or "not elevated" amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* English-speaking individuals (65-80 years old) with normal cognition
* Individuals with at least one first-degree relative with Alzheimer's disease (parent, sibling, child)
* Individuals who have a close friend, relative or spouse (18+) willing to be a study partner. Study partners complete surveys and interviews, accompany the study subject to the second in-person study visit, and may be asked to attend other/all study visits.
* Individuals who are willing to give a cheek swab sample to undergo blinded (undisclosed) APOE genotyping
* Individuals willing to participate in a randomized clinical trial of amyloid imaging disclosure

Exclusion Criteria

* Individuals who have suffered from a stroke or head trauma
* Individuals who have active medical or psychiatric illness that is unstable or progressive
* Individuals who are taking acetylcholinesterase inhibitors of memantine

Minimum Eligible Age

65 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes